jao
Abstract : Bevacizumab in Combination with FOLFIRI in the First-Line Treatment of Patients with Advanced Colorectal Cancer: A Single-Institution Experience
|
|
Abstract: Introduction: Bevacizumab combined with IFL (irinotecan, bolus 5-fluorouracil, and leucovorin) has been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC). However, infusional 5-fluorouracil-based combinations are now considered optimal in this setting. We analyzed the efficacy and toxicity of FOLFIRI (irinotecan, infusional 5-fluorouracil, and leucovorin)–bevacizumab in an unselected cohort of consecutive patients with mCRC. Materials and Methods: Patients with unresectable mCRC received bevacizumab 5 mg/kg and irinotecan 180 mg/m² on day 1, leucovorin 200 mg/m² on days 1 and 2, 5-fluorouracil 400 mg/m² bolus, and 600 mg/m² continuous infusion on days 1 and 2, every 14 days. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were assessed. Results: Overall, 127 patients were included (69% male, median age 64 years); 15 patients had diabetes, 40 had hypertension, and 23 were undergoing anticoagulant/antiplatelet therapy. Median PFS was 11.0 months (95% CI 10.0–12.0); median OS was 26.0 months (95% CI 21.9–30.1). The ORR was 55.1% (95% CI 46.3–63.6%), with 12 complete responses, 58 partial responses, and 44 patients with stable disease. Salvage surgery was performed in 31 patients (24%), including 23 with liver metastases and one with lung metastases. Grade 3/4 toxicities included neutropenia (17%), vomiting (6%), and diarrhea (17%); grade 3/4 bevacizumab-related toxicities included hypertension (2%), hemorrhage (2%), and venous (7%) and arterial thromboembolic events (5%). Conclusion: FOLFIRI–bevacizumab was active and tolerable in this cohort of unselected patients with mCRC, resulting in a high surgical rescue rate and prolonged survival. Keywords: Bevacizumab, colorectal cancer, FOLFIRI, anticoagulant therapy, surgical rescue.Download Full Article |
Abstract : Metabolic Alterations, Vascular Disease and Advanced Prostate Cancer: New Players for Metastatic Advanced Prostate Cancer?
|
|
Abstract: Introduction: Epidemiologic studies have implicated metabolic imbalance in prostate cancer (PCa) aggressiveness, nevertheless no clear consensus has been reached. The aim of the research was to investigate the association of hypertension, hypercholesterolemia and vascular disease in advanced PCa with and without bone metastases. Methods: Retrospective analysis of 66 patients with diagnosis of advanced PCa between 2005 and 2009 was conducted. We examined hypertension, hypercholesterolemia and vascular disease in 25 patients with advanced PCa and bone metastases versus 41 patients with advanced non-metastatic PCa. Men with incomplete data available, history of hormone therapy or chemotherapy, vascular surgery or other anticancer therapies were excluded. Results:Hypertensionwas significantly linked to advanced PCa with bone metastases (OR 4.5, p = 0.01). Hypercholesterolemia also was significantly associated with aggressive metastatic PCa (OR 3.28, p = 0.01). A significant association was noted between metastatic PCa and vascular disease (OR 3.8, p = 0.04). Conclusions:In our study,hypertension, hypercholesterolemia and vascular disease were significantly related to advanced metastatic PCa. Further research should elucidate these relations in larger samples to confirm these associations and to stabilize future prevention strategies. Keywords: Prostate Cancer, bone metastases, hypertension, dyslipidaemia, vascular disease.Download Full Article |
Abstract : Lipoidic Cells Ovary Cancer, Clinic Case and Literature Review
|
|
Abstract: Objective:Analyzed a case of woman with virilizan ovary tumor, where clinics manifestations made easy diagnosis of a anexial tumor producing masculine hormones with neoplastic thorax effusion and ascites. Specific tumoral serum marks for diagnosis, and posoperatory evolution. We made a medical prospective literature review. Methods:We studied a female case 35 years old, with an androgenic malignity ovary tumor, Analysis was worked ina Regional General Hospital of a State of Mexico, Mexico last year. Prospective studying a tumor of the ovary, produces masculine hormones. Discussion:Rare tumor, represents, almost 0.5% all ovarian tumors. It’s secrets masculine hormones; with broaden voice, acne, facial and corporal hair increased, large clitoris, androgenic calvicie patter. Those tumors grow in all age’s women groups, but usually in young women, almost is unilateral (95%). We show a clinical case of woman, 35 years old with androgenic dates, She carried out surgery for ovarian tumor. Histopathology report confirmed a malign ovary cordons sexual cells, with high malign grade compound, approximated 30 cm mayor diameter with integral capsule. Stage IC. Were used 6 cycles intravenous systemic chemotherapy. At present, her tumoral marks are negative and gradually have been disappeared androgenic clinical manifestations. Conclusions:Rare malign ovary tumor, produces androgenic clinical manifestation. Grove up tumor marks like serum testosterone; cytorreductive surgery is cornerstone treatment. Prognosis disease is up to grade of cell differentiation and stage in surgical-pathological events. Five years survive in stage I, is approximate in 70 to 90% of cases. Keywords: Lipoidic cells, virilizan, ovary cancer.Download Full Article |
Abstract : A Case Report of Visual Disturbance Caused by Thrombosis of the Superior Sagittal Sinus
|
|
Abstract: Superior sagittal sinus thrombosis is a rare condition caused by several diseases including malignancy. Major symptoms include headache, seizure, and motor weakness. Ocular sign is a minor symptom. The present case had visual disturbance caused by thrombosis of the superior sagittal sinus, which is an extremely rare case that was treated successfully by our team. Keywords: Cerebral venous thrombosis, Optic papilla, Congestion, Lung, Hypercoagulopathy, Squamous cell carcinoma..Download Full Article |
